US FDA Finalizes Human Factors Guidance: What It Means for Thai Submissions

On May 29, 2026, the US FDA published its final guidance, "Content of Human Factors Information in Medical Device Marketing Submissions," replacing the December 2022 draft. The document is confirmed via Federal Register entry 2026-10734, available at federalregister.gov/documents/2026/05/29/2026-10734. It is worth reading closely even for manufacturers with no active US filings, because the framework it introduces is likely to reshape how Thai FDA reviewers assess usability documentation over the next regulatory cycle.

What the Final Guidance Actually Changes

The guidance establishes a risk-based three-category system for documenting human factors engineering in premarket submissions. Category 1 covers low human-factors-risk devices, where a brief summary statement satisfies the requirement. Category 2 requires moderate documentation, including summative evaluation rationale and evidence that user interface risks have been adequately addressed. Category 3, reserved for the highest-risk devices, requires a full human factors engineering report with summative usability testing conducted under an approved protocol. The FDA has included worked examples and report templates for each tier to help manufacturers scope their documentation correctly rather than over- or under-building it.

Submissions filed before August 1, 2026 are not expected to fully incorporate the new framework, giving manufacturers a transition window to adjust internal documentation practices. The FDA will hold a Town Hall on July 22, 2026 to field implementation questions directly, and manufacturers wanting clarity on how a specific device is categorized should use that session, or the Q-submission pathway, to engage before filing under the final framework.

Why Thai FDA Reviewers Will Care

Thai FDA's CSDT technical file review already references IEC 62366-1, the usability engineering standard, as an expected component for Class 3 and Class 4 device submissions. Thailand has not adopted a formal tiered framework matching the US FDA's three categories, but US FDA human factors guidance has historically shaped IMDRF working group output, and through that channel it tends to reach ASEAN technical expectations within one to two regulatory cycles. Manufacturers designing for the Thai market have a real incentive to align their human factors documentation with the new three-category structure now, before that alignment becomes an explicit expectation rather than a forward-looking one.

The framework matters most for combination products, software-driven devices, and devices used in high-risk clinical environments where user error creates direct patient safety exposure. MDCD reviewers assessing Class 3 and 4 CSDT submissions have grown increasingly attentive to the usability engineering section, and a missing summative evaluation rationale or absent testing documentation is already a leading cause of deficiency notices in complex device categories. Building to the US FDA's three-category architecture gives a manufacturer a documentation structure that satisfies current Thai FDA expectations while positioning the file for whatever formalized standard Thai FDA eventually adopts.

What Manufacturers Should Do With This Now

Start by pulling the final guidance from the FDA's guidance search and working through the Category 1, 2, and 3 criteria in detail, including the templates and worked examples provided for each. Apply that risk-based logic to every device in the portfolio individually; category misclassification is a common submission error and generates FDA deficiency requests just as readily as it will eventually generate MDCD queries. The July 22, 2026 Town Hall is worth attending or reviewing afterward, since implementation questions specific to device types will be addressed directly, and registering in advance to submit questions ahead of time gets better coverage of edge cases.

Existing CSDT technical files for Class 3 and Class 4 devices deserve a look against this framework now, since a gap identified during an internal review is far cheaper to close than one raised in a Thai FDA deficiency response. Human factors engineering plans and summative evaluation reports should be revised to use the Category framework's language and structure, which keeps US FDA and Thai FDA submissions consistent and simplifies future audits. Combination products and software as a medical device submissions warrant particular attention, since both categories draw heightened scrutiny under the US framework and under IEC 62366-1 as Thai FDA applies it.

Human factors documentation is one of the more commonly deficient areas in CSDT files reviewed for Class 3 and 4 devices in Thailand, and the categories in the new US FDA guidance map closely to the risk stratification MDCD already applies under IEC 62366-1. DeeMED Consulting builds human factors documentation into CSDT technical file preparation from the start, so submissions satisfy current Thai FDA expectations while already tracking the international standard the market is moving toward. Manufacturers with a Class 3 or 4 device in preparation should treat a human factors documentation gap assessment as a pre-filing step, not an afterthought, and DeeMED's CSDT technical file preparation service covers exactly this review.